A Study to Evaluate Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or Refractory Multiple Myeloma

Other illness

• Waldenström’s macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or primary amyloid light-chain amyloidosis
• Participants with myelodysplastic syndrome

Lab values

• Plasma cell leukemia with circulating plasma cell count = 5% or >500/µL

Other

• Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the last dose of forimtamig, tocilizumab, or carfilzomib, or 102 days after the last dose of daratumumab
• Participants with current amyloidosis (e.g., positive Congo Red stain or equivalent in tissue biopsy)
• Participants with (extramedullary) lesions in proximity of vital organs that may develop sudden decompensation/deterioration in the setting of a tumor flare. Participants may be eligible after discussion with the Medical Monitor

• Agreement to provide protocol-specific bone marrow biopsy and aspirate samples
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
• Life expectancy of at least 12 weeks
• Documented diagnosis of MM according to the International Myeloma Working Group (IMWG) diagnostic criteria
• Evidence of progressive disease based on Investigator’s determination of response by IMWG criteria on or after last dosing regimen
• Participants with r/r MM who previously received therapy, including an immunomodulatory drugs (IMiDs) and a proteasome inhibitor (PI). Both anti-CD38 naïve and anti-CD38 exposed/refractory participants are allowed